Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A very rare, complex type of hereditary spastic paraplegia characterized by early-onset spastic paraplegia (with spasticity in the lower extremities that progresses to the upper extremities) associated with developmental and motor delay, mild to moderate cognitive and speech delay, skeletal dysmorphism (e.g. kyphosis and pectus), hypertrichosis and mildly impaired vibration sense. SPG53 is due to mutations in the VPS37A gene (8p22) encoding vacuolar protein sorting-associated protein 37A.
Features include always present findings: Joint hypermobility, Excessive outward curvature of the upper spine (kyphosis), Lower limb hypertonia, and Overactive reflexes (hyperreflexia); and common findings: Clonus, Delayed speech and language development, Upper limb hypertonia, and Hypertrichosis and others. 15 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 8 | Clonus, Delayed speech and language development, Difficulty walking (gait disturbance) |
VPS37A function has not been fully characterized.
Hereditary spastic paraplegia 53 is associated with mutations in the VPS37A gene on chromosome 8.
Genetic testing for VPS37A is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for hereditary spastic paraplegia 53 has been reported in the published literature.
Phenotype severity distribution: 4 always present features, 5 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for hereditary spastic paraplegia 53.
18 publications have been identified in PubMed for hereditary spastic paraplegia 53. Research spans Review / Meta-Analysis (35%), Case Report / Case Series (35%), and Diagnostic / Biomarker (12%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 6 | 35% |
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 5:36 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Bones and joints | 2 | Joint hypermobility, Excessive outward curvature of the upper spine (kyphosis) |
Arms and legs | 2 | Upper limb hypertonia, Lower limb hypertonia |
6 |
35% |
Testing and diagnosis research | 2 | 12% |
Disease patterns and progression | 2 | 12% |
New treatment approaches | 1 | 6% |
Alawadhi A (2026). [PMID: 42147656](https://pubmed.ncbi.nlm.nih.gov/42147656/). *Cureus*. [Case Report / Case Series]
Trilla P (2026). [PMID: 41758270](https://pubmed.ncbi.nlm.nih.gov/41758270/). *Cell Mol Neurobiol*. [Case Report / Case Series]
Sakai Y (2026). [PMID: 41756808](https://pubmed.ncbi.nlm.nih.gov/41756808/). *Autophagy Rep*. [Review / Meta-Analysis]
Pedullà G (2026). [PMID: 42150761](https://pubmed.ncbi.nlm.nih.gov/42150761/). *J Neurogenet*. [Review / Meta-Analysis]
Sartorelli J (2026). [PMID: 41650577](https://pubmed.ncbi.nlm.nih.gov/41650577/). *J Neurol Sci*. [Diagnostic / Biomarker]
Salari M (2025). [PMID: 40041249](https://pubmed.ncbi.nlm.nih.gov/40041249/). *Neurol Genet*. [Review / Meta-Analysis]
Jang E (2025). [PMID: 40587263](https://pubmed.ncbi.nlm.nih.gov/40587263/). *Biochem Soc Trans*. [Review / Meta-Analysis]
Damásio J (2025). [PMID: 41357347](https://pubmed.ncbi.nlm.nih.gov/41357347/). *Neurol Genet*. [Epidemiology / Natural History]
Lallemant-Dudek P (2025). [PMID: 39704400](https://pubmed.ncbi.nlm.nih.gov/39704400/). *Eur J Neurol*. [Epidemiology / Natural History]
Sardina F (2025). [PMID: 39920118](https://pubmed.ncbi.nlm.nih.gov/39920118/). *Cell Death Discov*. [Gene Therapy / Novel Therapeutics]